Microsoft’s withdrawal of services to Russia-backed Indian refiner Nayara Energy, last month, exposed the risks of relying on ...

Rosnilimab, a selective depleter of pathogenic T cells, is a potential game changer for the treatment of moderate-to-severe rheumatoid arthritis (RA).